ReviewHerzschrittmachertherapie & Elektrophysiologie2026
[Emergency pharmacotherapy in rhythmology].
Review in Herzschrittmachertherapie & Elektrophysiologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute cardiac arrhythmias are among the most common and prognostically relevant emergency situations in clinical cardiac electrophysiology. They range from bradycardia and supraventricular tachycardia to atrial fibrillation and atrial flutter to potentially life-threatening ventricular tachyarrhythmias and electrical storm. In these situations, rapid, structured and guideline-based pharmacotherapy is essential to prevent hemodynamic instability and mortality.The selection of appropriate emergency medication depends primarily on the underlying arrhythmia, the hemodynamic situation and individual patient factors such as structural heart disease, heart failure and comorbidities. In addition to classical antiarrhythmic drugs, substances that act on the atrioventricular (AV) node, beta blockers, calcium channel blockers, adenosine, glycosides and catecholamines also play a central role in acute treatment.As no new antiarrhythmic drugs have been approved for clinical practice in the past 15 years, established substances continue to be of particular importance. In addition, antiarrhythmic drugs that are not regularly available in Germany, such as procainamide or mexiletine, are also being discussed, as they may be prognostically relevant, particularly in complex bail-out situations involving ventricular arrhythmias.
Indexed as
Identifiers
41764149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.